- Home
- AVAH vs PHVS Comparison
AVAH vs PHVS Comparison
Compare AVAH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVAH
- PHVS
- Stock Information
- Founded
- AVAH 1984
- PHVS 2015
- Country
- AVAH United States
- PHVS Switzerland
- Employees
- AVAH N/A
- PHVS N/A
- Industry
- AVAH Hospital/Nursing Management
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AVAH Health Care
- PHVS Health Care
- Exchange
- AVAH Nasdaq
- PHVS Nasdaq
- Market Cap
- AVAH 872.6M
- PHVS 1.3B
- IPO Year
- AVAH 2021
- PHVS 2021
- Fundamental
- Price
- AVAH $8.39
- PHVS $23.38
- Analyst Decision
- AVAH Buy
- PHVS Strong Buy
- Analyst Count
- AVAH 5
- PHVS 5
- Target Price
- AVAH $7.50
- PHVS $35.60
- AVG Volume (30 Days)
- AVAH 1.3M
- PHVS 123.8K
- Earning Date
- AVAH 11-06-2025
- PHVS 11-12-2025
- Dividend Yield
- AVAH N/A
- PHVS N/A
- EPS Growth
- AVAH N/A
- PHVS N/A
- EPS
- AVAH 0.09
- PHVS N/A
- Revenue
- AVAH $2,177,672,000.00
- PHVS N/A
- Revenue This Year
- AVAH $16.37
- PHVS N/A
- Revenue Next Year
- AVAH $6.62
- PHVS N/A
- P/E Ratio
- AVAH $88.02
- PHVS N/A
- Revenue Growth
- AVAH 11.54
- PHVS N/A
- 52 Week Low
- AVAH $3.67
- PHVS $11.51
- 52 Week High
- AVAH $8.54
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AVAH 76.89
- PHVS 55.19
- Support Level
- AVAH $8.05
- PHVS $23.20
- Resistance Level
- AVAH $8.54
- PHVS $24.83
- Average True Range (ATR)
- AVAH 0.30
- PHVS 1.34
- MACD
- AVAH -0.07
- PHVS -0.02
- Stochastic Oscillator
- AVAH 86.24
- PHVS 58.45
About AVAH Aveanna Healthcare Holdings Inc.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.